Work

Use of etanercept in management of tyrosine kinase-inhibitor-induced erythema nodosum

Year: 2020

Type: article

Abstract: Erythema nodosum (EN) can occur in patients receiving tyrosine kinase inhibitors (TKI), and it resolves with cessation of the offending drug. Sometimes, the medication can be continued and the EN suppressed by systemic corticosteroids.1 We present an instance of TKI-induced EN in a patient with chronic myeloid leukemia (CML) that was refractory to oral and intralesional corticosteroids but was successfully treated with etanercept, allowing for resumption of targeted chemotherapy.

Source: JAAD Case Reports

DOI: 10.1016/j.jdcr.2020.04.016

Authors: Erisa Alia, Aakaash Varma, Joshua Brody, Alla Keyzner, Rajendra Singh, Jacob Levitt

Institutions: University of Connecticut, UConn Health, SUNY Downstate Health Sciences University, Mount Sinai Hospital

Language: English

Topic: Chemotherapy-related skin toxicity

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $600